Lexicon Pharmaceuticals (LXRX) Invested Capital (2023 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed Invested Capital for 6 consecutive years, with $112.1 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital fell 23.17% to $112.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.1 million, a 23.17% decrease, with the full-year FY2025 number at $112.1 million, down 23.17% from a year prior.
- Invested Capital was $112.1 million for Q4 2025 at Lexicon Pharmaceuticals, down from $120.2 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $288.9 million in Q1 2024 to a low of $93.1 million in Q4 2023.
- A 3-year average of $177.8 million and a median of $155.5 million in 2024 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: surged 111.09% in 2024, then plummeted 46.06% in 2025.
- Lexicon Pharmaceuticals' Invested Capital stood at $93.1 million in 2023, then soared by 56.75% to $146.0 million in 2024, then fell by 23.17% to $112.1 million in 2025.
- Per Business Quant, the three most recent readings for LXRX's Invested Capital are $112.1 million (Q4 2025), $120.2 million (Q3 2025), and $129.4 million (Q2 2025).